logo
Brandi Glanville Details New Treatment for Facial Disfiguration, Reveals If She'd Get Filler Again

Brandi Glanville Details New Treatment for Facial Disfiguration, Reveals If She'd Get Filler Again

Yahoo11 hours ago
Thanks to social media, Brandi Glanville has a new doctor and new treatment in place as her years-long battle with facial disfigurement continues. The 52-year-old Real Housewives of Beverly Hills alum told Us Weekly exclusively that she 'randomly' met New York City-based 'infectious disease doctor' Dr. Michael Scoma online and he's hoping to help. 'He specializes in super hard to treat things where people can't get a diagnosis,' Glanville explained to Us. The first course in her treatment is 'IV antibiotics and fungal medications' through a PICC line in Glanville's arm. Glanville admitted that she's 'a wreck' as her health battle continues but is trying to keep a positive mindset. 'I always joke my life is like The Last of Us? I'm just turning into one of those black mold people,' Glanville said. 'That's how I felt. I have lumps on my face and they're moving around.' What Brandi Glanville Has Said About Her Facial Disfigurement: Treatments, Teeth and Mental Health Glanville told Us it was 'the strangest feeling' to know something was moving around in her face. 'Dr Michael Scoma said he wouldn't know if there was a parasite or not, because he didn't treat me early on. But if there was, it would have been gone by now,' she said. 'A lot of this infection, in this deep tissue — the staph infection, and there's other problems happening — it mimics a parasite. It has this fluid that jumps around your face because it's spreading.'Initially, it was just her face. Now, the infection has spread to Glanville's 'whole' head, neck, shoulder, collarbone and down her left arm. 'I spent two years being told there was really not anything wrong with me,' she explained. Glanville's health issues started when she returned home from Morocco in January 2023 after filming The Real Housewives Ultimate Girls Trip season 4, discovering that she had contracted a parasite. (Glanville left the show after she was accused of sexual misconduct during filming by costar Caroline Manzo, which she has vehemently denied.) 'It's definitely calmed down since I was treated for the parasite, but now I'm left with [an] infection in my skin,' she told Us, noting that 'fluid' often leaks out of her ear and her face is 'all sunken in' — all things she hopes to cure with the help of Dr. Scoma. 'Right now, our focus is on treating Brandi's long-standing infection and its secondary effects,' Scoma told Us exclusively. 'Once the infection is fully controlled and she's stable, we can evaluate any next steps to support her recovery.' Scoma has taken a 'proactive' approach to Glanville's health issues with a 'multi-phase treatment.' The IV antibiotics Glanville discussed with Us are the first step — and only a short-term solution. Scoma eventually plans to give Glanville 'long-term maintenance' via oral antibiotic therapy with 'close monitoring.' He will also make 'adjustments' based on her response. Brandi Glanville Reveals She's Spent Over $113K on Health Issues, Misses 'Living Life' 'We can expect to see meaningful progress within the next few weeks, and I do believe Brandi can make a full recovery,' Scoma added. Glanville must follow Scoma's 'treatment protocols closely' and kick off her healing journey with 'proper rest' and 'a protein rich diet,' he told Us. She also must incorporate 'accessible strategies that support immunological health, like staying hydrated, managing stress, and maintaining key nutrients.' Along with Dr. Scoma, the former reality star also teamed up with 'angel' healthcare strategist Rachel Strauss, who is also known as the PBM Princess, to help with her medical bills. 'She advocates for people who have tons of medical bills. When you're sick and they're piling up, that causes stress and it makes your medical issues worse,' Glanville told Us, revealing that she has 'well over' $130,000 in medical bills. Strauss told Us that she hopes to 'recoup some of [Glanville's] money back' as they work together. 'I don't know that we're gonna be able to wipe a fat $100,000 away, but what we are going to be able to do is make sure that the proper parties who have to pay for those claims pay for them,' she said. 'Where it does fall on her responsibility is working with the hospitals she saw, reviewing what was billed, making sure it was billed properly — because certain things were truly emergencies that doctors will validate — and getting those reduced however we can.' Brandi Glanville Pixie Productions Former 'Real Housewives of Beverly Hills' Stars: Where Are They Now? Glanville has seen 21 doctors (which has led to her medical debt) as she navigates her health issues, and some have blamed her facial disfigurement on 'old filler,' referring to past cosmetic procedures. She also made it clear to Us that there aren't any trips to a plastic surgeon in the near future — but is hoping to get a facelift one day. 'The doctor actually said my skin should regenerate quite a bit — not as much as I would like — because they did dissolve so much,' she shared. 'But it's going to be at least a year before I can do anything cosmetic, and I won't ever get an injection again.' When Dr. Scoma was asked about Glanville potentially getting cosmetic surgery again, he told Us, 'Right now, our focus is on treating Brandi's long-standing infection and its secondary effects. Once the infection is fully controlled and she's stable, we can evaluate any next steps to support her recovery.'
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novo Nordisk to offer Ozempic at $499 per month to cash-paying US customers
Novo Nordisk to offer Ozempic at $499 per month to cash-paying US customers

Yahoo

time23 minutes ago

  • Yahoo

Novo Nordisk to offer Ozempic at $499 per month to cash-paying US customers

(Reuters) -Novo Nordisk said on Monday that it was launching a new offer for self-paying type 2 diabetes patients in the U.S. to access Ozempic for $499 per month. The company said this was part of its ongoing efforts to explore new collaborations and approaches towards improving access to authentic semaglutide medicines. It said the offer would be available through multiple platforms, including through telehealth service GoodRx. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Novo Halves Ozempic Price to $499 a Month for Those Paying Cash
Novo Halves Ozempic Price to $499 a Month for Those Paying Cash

Bloomberg

time26 minutes ago

  • Bloomberg

Novo Halves Ozempic Price to $499 a Month for Those Paying Cash

Novo Nordisk A/S is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for high US drug prices. Patients can now get Ozempic for $499 a month — about half of its US list price — through Novo's cash-pay pharmacy NovoCare, the company said in a statement Monday. It's also partnering with GoodRx Holdings Inc. to offer Ozempic and its sister weight-loss drug Wegovy for the same price at pharmacies across the US.

Why Nova Nordisk (NVO) Stock Is Climbing Today
Why Nova Nordisk (NVO) Stock Is Climbing Today

Yahoo

timean hour ago

  • Yahoo

Why Nova Nordisk (NVO) Stock Is Climbing Today

Aug 18 - Novo Nordisk won accelerated FDA approval for Wegovy to treat metabolic-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, expanding the GLP-1 therapy's reach. The decision follows Part 1 of the ESSENCE trial, where 37% of patients on Wegovy improved fibrosis versus 22% on placebo, and nearly twice as many saw inflammation resolve. Novo said the drug will be available immediately in the U.S. and should pair with diet and exercise. Warning! GuruFocus has detected 1 Warning Sign with NVO. Shares rose about 3% early trading as investors digested the news following a sell-off after the company trimmed its 2025 sales outlook. The approval makes Wegovy the first GLP-1 cleared for MASH and the second FDA-approved liver drug after Madrigal Pharmaceuticals' Rezdiffra, intensifying competition. Madrigal (MDGL) shares fell, while Eli Lilly (LLY) faces added pressure as it advances tirzepatide trials. Analysts estimate the MASH market could reach $30 billion, depending on pricing, reimbursement, and rollout. Novo filed for Wegovy use in Europe and Japan and expects final ESSENCE Part 2 results in 2029. Investors should watch access, pricing decisions, and payer negotiations as key drivers for revenue and margins. This article first appeared on GuruFocus. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store